Fibrodysplasia ossificans progressiva (fop)
Drug research and approvals for fibrodysplasia ossificans progressiva (fop): what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 4 studies of fibrodysplasia ossificans progressiva (fop) are recruiting on ClinicalTrials.gov, Health Canada has authorized 5 drug trials for it since 2013, and FDA has 3 approved and 2 open orphan designations naming it.
- Recruiting worldwide: 4
- Trials authorized in Canada: 5
- FDA orphan approvals: 3
- EU medicines: 0
Recruiting Now
Newest start dates first, of 4 recruiting on ClinicalTrials.gov ↗- IL1 Inhibition in FOPNCT06724562 · Not reported · University of California, San Francisco · starts Apr 1, 2025
- A Study to Document and to Further Describe Long-term Safety and Effectiveness of Palovarotene in Participants With…NCT06089616 · Not reported · Ipsen · starts Dec 5, 2024
- To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans…NCT05090891 · Phase 2 · Incyte Corporation · starts May 5, 2022
- The Fibrodysplasia Ossificans Progressiva (FOP) RegistryNCT02745158 · Not reported · The International FOP Association · starts Jul 1, 2015
Trials Authorized in Canada
Newest first; search them all in Canada trials| Dec 21, 2021 | Rollover study; multicentre, phase III, open-label study to further evaluate the safety and efficacy of palovarotene capsules in male and female participants…PALOVAROTENE | Ipsen | Closed |
| Nov 25, 2021 | A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of incb000928 in participants with…ZILURGISERTIB (INCB000928) | Incyte Corporation | Ongoing |
| Dec 30, 2020 | A phase 2, two-part, placebo-controlled, parallel-group, double-blind study to assess the efficacy adn safety of 2 dosage regimens of oral ipn60130 for the…FIDRISERTIB (IPN60130) | CLEMENTIA PHARMACEUTICALS INC. | Closed |
| Aug 10, 2018 | A randomized, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, and effects on heterotopic bone formation of regn2477 in patients…REGN2477 | Regeneron | Pending |
| Nov 8, 2017 | A phase 3, efficacy and safety study of oral palovarotene for the treatment of fibrodysplasia ossificans progressiva (fopPALOVAROTENE | CLEMENTIA PHARMACEUTICALS INC. | Closed |
FDA Orphan Designations
Approved first, then open designations, newest first| Sep 25, 2026 | Atebriozto reduce the volume of total new heterotopic ossification (HO) in adults and pediatric patients aged 12 years and older with… | Mirum Pharmaceuticals, Inc. | Approved |
| Aug 19, 2026 | Pasatruto reduce formation of new heterotopic ossification (HO) lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans… | Regeneron Pharmaceuticals, Inc. | Approved |
| Aug 16, 2023 | Sohonosfor the reduction in volume of new heterotopic ossification in adults and pediatric patients aged 8 years and older for females and 10… | Ipsen Biopharmaceuticals, Inc. | Approved |
| Oct 22, 2026 | saracatinibtreatment of fibrodysplasia ossificans progressiva | Mass General Brigham | Designated |
| Mar 19, 2024 | AndecaliximabTreatment of fibrodysplasia ossificans progressiva | ashibio Inc | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA